Senior Executives Highlight Mergers and Acquisitions and Expansions at DCAT Week ’18

At the DCAT Member Company Announcement Forum, held during DCAT Week, senior executives from member companies of the Drug, Chemical & Associated Technologies Association (DCAT) provided the latest major news from their companies impacting the pharmaceutical manufacturing value chain. So what did they report?

The executives highlighted key strategic activity, including mergers and acquisitions (M&A), post-M&A integration, and manufacturing expansions. Lonza, DowDuPont, Catalent, Novasep, CordenPharma, Piramal Pharma Solutions, SK biotek, Biocon, Procos, Nosco, AB BioTechnologies, and PolyCrystalLine were among the companies taking the podium to provide their latest developments.

The executives highlighted developments to expand active pharmaceutical ingredient (API) development and manufacturing (both small molecules and biologics), drug-product development and manufacturing (both solid dosage and parenteral drugs), and packaging. A roundup of these developments are provided in the stories below.

Lonza Updates Integration of $5.5-Billion Acquisition of Capsugel

DowDuPont Outlines Integration of Combined Company, Including Excipients Business

Catalent Updates Integration of $950-Million Acquisition of Cook Pharmica

Novasep Announces $65-Million Investment in Biologics

CordenPharma Outlines Integration of Former Pfizer API Facility

Piramal Pharma Solutions CEO Outlines Expansion Plans

SK biotek Outlines Integration of Former BMS API Manufacturing Facility

Biocon COO Highlights Company’s Growth Strategy

Procos CEO Outlines Expansion for High-Potency Manufacturing

Nosco President Discusses Company’s Growth Strategy in Wake of Two Key Acquisitions

AB BioTechnologies CEO Announces $12-Million Expansion

PolyCrystalLine CEO Announces Expansion of Solid-State Chemistry Capabilities

Leave a Reply

Your email address will not be published. Required fields are marked *

Recent Feature Articles

The CDMO/CMO & Suppliers’ Report: The Rising Strength of Tides

By
Double-digit growth is projected for the markets for peptide and oligonucleotide synthesis, creating opportunities for CDMOs/CMOs.

The Financial Squeeze on Emerging Pharma and Early-Stage Innovation

By
Access to public or private funding remains an existential challenge to fuel early-stage innovation as the biotech industry seeks to recover from a constrained financial & deal-making environment.

Small-Molecule Drugs: Top 10 Market, Sourcing, and Supply-Chain Trends

By
What are key trends and issues that are on the industry’s radar for small-molecule drugs? DCAT Value Chain Insights examines market share, growth rates, product innovation, and API supply chains.

FDA’s Draft Guidance on Platform Technology Designation: The Mfg Impact

By
The FDA has issued much-awaited draft guidance that details how it plans to implement its new platform technology designation program. What does it mean for manufacturing overall and in specific sectors—biologics and advanced therapies?